March 13, 2026 5:14pm

Capping the week, indexes are Still under pressure from econs’ rise, fall, revisions and oil “conflagration” or war or inclusion

GDP revised down to just 0.7% growth with January core inflation was 3.1%

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF, NO “tuners” to celebrate today, cold medicines only

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

 

RMi Pre-opening: Friday, the 13th … https://www.regmedinvestors.com/articles/14347   

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt, barely fulfills the need of a PPM raise … https://www.regmedinvestors.com/articles/13812

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The Dow closed DOWN -119.38 points or -0.26%, the S&P closed DOWN -40.43 points or -0.61% while the Nasdaq closed DOWN -206.62 points or -0.94%

  • Theme of the session: oil and “undeclared” war thus a conflagration or incursion?

Friday’s (my) 40-company covered sector’s advance/decline line opened negative with 5 incliners, 32 decliners and 3 flats, ending with a negative close of 11 incliner, 24 decliners and 5 flats

  • The C&GT sector is STILL succumbing to short-termitis

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The Job Openings and Labor Turnover Survey showed openings rose by to 6.9 M, an increase of 396,000 from the prior month. As a share of the labor force, the vacancy rate rose to 4.2%, or an increase of 0.2% point. The FactSet consensus outlook was for 6.7 M.
  • Consumer sentiment was little changed in March, the University of Michigan reported in its Survey of Consumers posted a headline reading of 55.5, down 1.9% from February and close to the consensus forecast for 55.3. The current conditions index rose 2.1% while the expectations index fell 4.4%.
  • GDP or gross domestic product, a measure of all the goods and services produced across the sprawling U.S. economy, rose at a seasonally and inflation-adjusted annual rate of just 0.7% in Q4 … the 1st revision of the GDP reading was a sharp step down from the previous estimate of 1.4% and well below the consensus forecast for 1.5%. It also marked a considerable slowdown from the 4.4% gain in the prior period.

The CBOE Fear (VIX) index, Friday closed 27.19, after Thursday’s 27.27, Wednesday’s 24.31, Tuesday’s 25.46, Monday’s 25.54, and last Friday’s 20.49,

Metrics: Friday …

  • The RUT was down -8.94 points or -0.36%,
  • The XLV was down -0.37 points or -0.25%,
  • The NBI was down -30.75 points or -0.57%;
  • The XBI was down -0.79 points or -0.64%
  • The IWM was down -0.82 or -0.33%;
  • The IBB was down -0.72 points or -0.43%,
  • The VIX was down -0.10 points or -0.37% at to 27.19

 

Q1/26 – March – 3 positive and 7 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Friday Closing UP (11 of 11) 

  • IQAI Holdings (IQV +$1.79 after Thursday’s -$8.64 after Wednesday’s +$0.69 after Tuesday’s -$7.64 after Monday’s +$4.06),
  • BioNTech (BNTX +$1.09),
  • AxoGen (AXGN +$0.58),
  • Vericel (VCEL +$0.42),
  • Lenz Therapeutics (LENZ +$0.33),
  • Precigen (PGEN +$0.23),
  • BioLife Solutions (BLFS +$0.21 after Thursday’s -$0.86 after Wednesday’s +$0.34 after Tuesday’s -$1.23),
  • Agenus (AGEN +$0.12),
  • Cellectis SA (CLLS +$0.09),
  • Arrowhead Pharmaceuticals (ARWR +$0.04 after Thursday’s -$3.09 after Wednesday’s -$1.10 after Tuesday’s +$1.47),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.01 with1 K shares traded) – Ponzi Scheme!

Flat (5)

  • Brainstorm Cell Therapeutics (BCLI)
  • Compass Therapeutics (CMPX)
  • Fate Therapeutics (FATE)
  • Generation Bio (GBIO) – acquired
  • MiMedx (MDXG)

Friday’s Closing DOWN (10 of 24): 

  • Vertex (VRTX -$8.79 after Thursday’s -$14.25 after Wednesday’s -$6.79 after Tuesday’s +$38.30 after Monday’s +$4.18),              
  • Alnylam Pharmaceuticals (ALNY -$3.82 after Thursday’s -$3.20 after Wednesday’s -$1.95 after Tuesday’s -$1.21 after Monday’s +$2.93),
  • Capricor Therapeutics (CAPR -$2.92),
  • uniQure NV (QURE -$1.41),
  • Ionis Pharmaceuticals (IONS -$1.15 after Thursday’s -$2.45 after Wednesday’s -$0.87 after Tuesday’s +$0.30 after Monday’s +$1.32),
  • Moderna (MRNA -$0.83 after Thursday’s -$2.58 after Wednesday’s +$0.99 after Tuesday’s -$0.76 after Monday’s +$3.22),
  • Sarepta Therapeutics (SRPT -$0.64),
  • Supernus Therapeutics (SUPN -$0.55 after Thursday’s -$2.76),
  • Mesoblast (MESO -$0.52),
  • Regenxbio (RGNX -$0.51),

 

 

The Bottom Line: More of the … WHY

Didn’t loose everything at/in the big casino … all 3 major averages closed out their 3rd consecutive week of losses.

Stocks followed swings in oil prices all week. The market initially rallied at Friday's open, despite the Bureau of Economic Analysis slashing its Q4 GDP - gross domestic product growth estimate in half to 0.7%.

  • The BEA also released a January core personal consumption expenditures price index that was hotter than economists anticipated. <Barron’s>

Reiterating … Data released Friday also showed US economic growth slowed more than initially thought in the final 3 months of 2025.

  • Real gross domestic product (GDP) for the fourth quarter was revised to 0.7% growth from a previous reading of 1.4%, the Bureau of Economic Analysis reported Friday.
  • In other economic news, a preliminary reading of March consumer sentiment hit its lowest level so far this year, while the Job Openings and Labor Turnover survey (JOLTS) showed job openings ticked up in February.
  • The University of Michigan's Index of Consumer Sentiment showed sentiment at 55.5 in an early March reading, down 1.9% from last month and below last year's level of 57. The decrease was greater than the 54.8 reading economists expected and marked the lowest reading so far this year.

Expectation:  Renewed inflation worries, combined with gains in oil prices, have shifted prospects for Fed policies. Traders have scaled back bets that the Fed will cut interest rates this year, but are now assessing fresh data to test those expectations

 

Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)
  • Thursday – 3/5 – Regenxbio (RGNX), Compass therapeutics (CMPX)
  • Thursday – 3/12 – Capricor Therapeutics (CAPR)
  • Monday – 3/16 – Agenus (AGEN)
  • Wednesday – 3/25 – Precigen (PGEN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 2nd week

  • 3/13 – Friday closed negative with 11 incliner, 24 decliners and 5 flats
  • 3/12 – Thursday closed negative with 1 incliner, 36 decliners and 3 flats
  • 3/11 - Wednesday closed negative with 11 incliners, 26 decliners and 2 flats
  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: IQIA Holdings (IQV), BioNTech (BNTX) and AxoGen (AXGN)
  • Thursday: Voyager Therapeutics (VYGR)
  • Wednesday: BioNTech (BNTX), AxoGen (AXGN) and Moderna (MRNA)
  • Tuesday: Vertex (VRTX), Capricor Therapeutics (CAPR) and Dyne Therapeutics (DYN)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and UniQure NV (QURE)

The worst three (3) in the session: Losers

  • Friday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Capricor Therapeutics (CAPR)
  • Thursday: Vertex (VRTX), IQIA Holdings (IQV) and Alnylam Pharmaceuticals (ALNY)
  • Wednesday: Vertex (VRTX), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: BioNTech (BNTX), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Monday: Mesoblast (MESO) and Compass Therapeutics (CMPX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.